On October 15, 2025, Corcept Therapeutics announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its selective glucocorticoid receptor antagonist, relacorilant, in the treatment of platinum‑resistant ovarian cancer. The MAA is supported by positive results from the pivotal Phase 3 ROSELLA trial and Phase 2 studies, which demonstrated improved progression‑free and overall survival when relacorilant was combined with nab‑paclitaxel.
Relacorilant is an oral therapy that selectively blocks the glucocorticoid receptor without affecting other hormone receptors, and it has been granted orphan drug designation by the European Commission for ovarian cancer. The EMA submission brings Corcept one step closer to regulatory approval in Europe, where an estimated 20,000 women in the United States and a comparable number in Europe are candidates for a new therapy each year.
The FDA is currently reviewing Corcept’s application for the United States, and the company’s MAA submission to the EMA underscores its strategy to expand the relacorilant portfolio beyond hypercortisolism into oncology. Successful approval would open a significant new market for Corcept, potentially generating substantial revenue and reinforcing the company’s position as a leader in selective cortisol modulation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.